October 24, 2022 02:49 PM EDTUpdated 03:55 PM
Pharma

Phar­ma lob­by­ing head­ed for record-break­ing 2022, non­prof­it says

Nicole DeFeudis

Editor

Phar­ma’s lob­by­ing ex­pens­es reached record heights last year — and ac­cord­ing to the lat­est re­ports, the in­dus­try is on track to top those num­bers in 2022 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Ab­b­Vie part­ners with Neo­morph in lat­est mol­e­c­u­lar glue deal

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Sam­sung Bio hits rev­enue high, se­cures largest con­tract to date

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times